BIOPHYTIS (ALBPS.PA) Stock Price, Forecast & Analysis

Europe • Euronext Paris • EPA:ALBPS • FR001400OLP5

0.0573 EUR
+0 (+0.53%)
Last: Feb 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership

ALBPS.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap656.67K
Revenue(TTM)N/A
Net Income(TTM)-8.03M
Shares11.46M
Float11.34M
52 Week High0.4
52 Week Low0.06
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.84
PEN/A
Fwd PEN/A
Earnings (Next)07-09
IPO2015-07-13
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ALBPS.PA short term performance overview.The bars show the price performance of ALBPS.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ALBPS.PA long term performance overview.The bars show the price performance of ALBPS.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALBPS.PA is 0.0573 EUR. In the past month the price decreased by -6.4%. In the past year, price decreased by -80.37%.

BIOPHYTIS / ALBPS Daily stock chart

ALBPS.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
ALBPS.PA Full Technical Analysis Report

ALBPS.PA Financial Highlights

Over the last trailing twelve months ALBPS.PA reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 87.11% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -121.24%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%89.18%
Sales Q2Q%N/A
EPS 1Y (TTM)87.11%
Revenue 1Y (TTM)N/A
ALBPS.PA financials

ALBPS.PA Forecast & Estimates

9 analysts have analysed ALBPS.PA and the average price target is 0.79 EUR. This implies a price increase of 1270.68% is expected in the next year compared to the current price of 0.0573.

For the next year, analysts expect an EPS growth of 48.09% and a revenue growth -78.57% for ALBPS.PA


Analysts
Analysts84.44
Price Target0.79 (1278.71%)
EPS Next Y48.09%
Revenue Next Year-78.57%
ALBPS.PA Analyst EstimatesALBPS.PA Analyst Ratings

ALBPS.PA Ownership

Ownership
Inst Owners3.07%
Ins Owners0.42%
Short Float %N/A
Short RatioN/A
ALBPS.PA Ownership

ALBPS.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
1AE ARGENX SE28.1543.912B
ARGX ARGENX SE27.843.875B
22UA BIONTECH SE-ADR N/A22.723B
ABVX ABIVAX SA N/A7.923B
2X1 ABIVAX SA N/A7.923B
GXE GALAPAGOS NV N/A1.874B
GLPG GALAPAGOS NV N/A1.871B
IVA INVENTIVA SA N/A1.027B
NANO NANOBIOTIX N/A1.009B
6IV INVENTIVA SA N/A978.821M

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges

About ALBPS.PA

Company Profile

ALBPS logo image Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 18 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.

Company Info

BIOPHYTIS

14 avenue de l'Opera

Paris ILE-DE-FRANCE FR

Employees: 22

ALBPS Company Website

ALBPS Investor Relations

Phone: 33141836600

BIOPHYTIS / ALBPS.PA FAQ

What does ALBPS do?

Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 18 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.


What is the current price of ALBPS stock?

The current stock price of ALBPS.PA is 0.0573 EUR. The price increased by 0.53% in the last trading session.


What is the dividend status of BIOPHYTIS?

ALBPS.PA does not pay a dividend.


How is the ChartMill rating for BIOPHYTIS?

ALBPS.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is the expected growth for ALBPS stock?

The Revenue of BIOPHYTIS (ALBPS.PA) is expected to decline by -78.57% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the number of employees for BIOPHYTIS?

BIOPHYTIS (ALBPS.PA) currently has 22 employees.


When does BIOPHYTIS (ALBPS.PA) report earnings?

BIOPHYTIS (ALBPS.PA) will report earnings on 2026-07-09.